Oct 30, 2019 8:30 am EDT Emerald Bioscience to Present Research Data Related to its Glaucoma Drug Candidate, NB1111, at 2019 American Association of Pharmaceutical Scientists
Oct 15, 2019 8:35 am EDT Emerald Bioscience’s NB1111 Demonstrates Superiority in Lowering Intraocular Pressure Compared to Global Standard of Care Glaucoma Treatment in Preclinical Model
Oct 15, 2019 8:30 am EDT Glauconix Presents Data Validating Impact of Emerald Bioscience’s Prodrug on the Ocular Endocannabinoid System in Glaucoma
Oct 3, 2019 8:30 am EDT Glauconix Biosciences and University of Mississippi to Present Research Data Related to Emerald Bioscience’s Glaucoma Drug Candidate, NB1111, at 2019 American Academy of Ophthalmology Annual Meeting
Aug 27, 2019 8:30 am EDT Emerald Bioscience to Participate in Investment and Scientific Conferences in September
Aug 26, 2019 8:30 am EDT Emerald Bioscience Appoints Chief Medical Officer and Executive Director, Clinical Operations
Aug 13, 2019 8:30 am EDT Emerald Bioscience Starts Australian Operation Ahead of Planned Glaucoma Study
Jun 19, 2019 7:00 am EDT Emerald Bioscience to Participate in 29th Annual International Cannabinoid Research Symposium (ICRS)
Jun 4, 2019 8:00 am EDT Emerald Bioscience’s NB2222 Exhibits Superior Ocular Permeation into Multiple Compartments of the Eye Compared to Cannabidiol